tbuckley/cabot-search huggingface dataset:
Ratio of waist circumference to height is better predictor of death than body mass index
Authors: B. D Cox, M. J Whichelow
Journal: BMJ (1996)

EDITOR,—The ratio of waist circumference to height has been shown to be a stronger predictor of intra-abdominal fat than the body mass index,1 and this must partly explain why this ratio showed a stronger association with cardiovascular risk than did body mass index in a cross sectional study.2 Height, weight, and waist and hip circumference were measured in the 1984–5 health and lifestyle survey of a nationwide random stratified sample of British adults.3 All participants in the survey were flagged on the central health service …
Light and Air
Authors: George N. Braman
Journal: Annals of Internal Medicine (1998)

Ad Libitum15 April 1998Light and AirGeorge N. Braman, MDGeorge N. Braman, MDBronx, NY 10471Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-8-199804150-00006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Like Quixote, I tilt at all that ... Author, Article, and Disclosure InformationAffiliations: Bronx, NY 10471Corresponding Author: George N. Braman, MD, 6142 Delafield Avenue, Bronx, NY 10471. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1998Volume 128, Issue 8Page: 647KeywordsBurnsHand strength ePublished: 15 August 2000 Issue Published: 15 April 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Successful treatment of acquired factor VIII inhibitors with cyclosporin
Authors: Alan G. Brox, Horace Laryea, Marc Pelletier
Journal: American Journal of Hematology (1998)

The treatment of Factor VIII inhibitors remains controversial and no standard therapy exists. We describe in this report two consecutive patients with this inhibitor that responded to cyclosporin. Clinical improvement of the bleeding diathesis, a return to normal of the PTT, a decrease in the level of the inhibitor, and a return to normal of the factor VIII level followed use of this drug. We believe that cyclosporin is effective in the treatment of factor VIII inhibitors and deserves further investigation.
77 Risk of hospitalization for psychiatric disorder after hospitalization for paracetamol or other drug poisoning — A Danish nation-wide registry-based case-control study
Authors: P. Jepsen, P.B. Mortensen, B. Nørgård, E. Agerbo, P. Qin, H. Vilstrup, H.T. Sørensen
Journal: Journal of Hepatology (2004)
Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease
Authors: Lin Xie, Joji Yui, Akiko Hatori, Tomoteru Yamasaki, Katsushi Kumata, Hidekatsu Wakizaka, Yuichiro Yoshida, Masayuki Fujinaga, Kazunori Kawamura, Ming-Rong Zhang
Journal: Journal of Hepatology (2012)
350 CLINICAL FACTORS PREDICTING ADVANCED LIVER FIBROSIS IN HEPATITIS B E ANTIGEN POSITIVE CHRONIC HEPATITIS B
Authors: H.L. Chan, G.L. Wong, P.C. Choi, A.W. Chan, A.M. Chim, K.K. Yiu, H.Y. Chan, V.W. Wong
Journal: Journal of Hepatology (2009)
Cryosurgical ablation of the A-V node-His bundle: a new method for producing A-V block.
Authors: L Harrison, J J Gallagher, J Kasell, R H Anderson, E Mikat, D B Hackel, A G Wallace
Journal: Circulation (1977)

A cryosurgical instrument was used to ablate atrioventricular conduction. The procedure was carried out in 20 dogs and subsequently in three patients with drug resistant, life-threatening supraventricular tachycardias. In patients, the cryosurgical unit lowered the temperature of the His bundle area to 0 degrees C, effecting complete but reversible heart block. Rewarming resulted in resumption of normal atrioventricular conduction. The His bundle region then was cooled to -60 degrees C; complete heart block was produced with two or more 90-120 second freezes. Postoperative evaluations revealed persistent atrioventricular conduction block. The lesion showed no tendency to rupture, form aneurysm, or interfere with valvular function. In the clinical cases, postoperative studies demonstrated a stable pacemaker arising proximal to the branching portion of the His bundle. A potential application of the cryosurgical technique might be ablation of sites of dysrhythmia (i.e., ectopic foci, re-entry circuits, accessory pathways).
A COMPARISON OF THE UREA NITROGEN CONTENT OF CUTANEOUS AND VENOUS BLOOD BY MICRO GASOMETRIC ANALYSIS
Authors: Christopher Johnston
Journal: Journal of Clinical Investigation (1930)

Svensgaard (1) using the micro urea method of Rehberg (2) com- pared the urea concentrations in blood from the arm vein with that of cutaneous blood from the lobe of the ear.In 29 of 32 analyses of the blood of normal fasting subjects she found the urea of the capillary blood higher thamn that of the venous blood.The average difference was 10 per cent of the venous urea content, but individual differences were as high as 24 per cent.Such results, if confirmed, would indicate that the use of cutaneous blood from the ear for analysis could intro- duce errors up to 24 per cent in tests of renal function, such as the blood urea clearance used in this clinic (3, 4, 5), which depend upon
The Oral Lesions of Monocytic Leukemia
Authors: Francis P. McCarthy, Paul H. Karcher
Journal: New England Journal of Medicine (1946)

IN REPORTING this case of subacute monocytic leukemia, the oral lesions are particularly stressed, since they dominated the clinical picture almost from the onset of the blood dyscrasia.Oral lesions represent a frequent and early finding in the various types of leukemia, especially in the acute forms. In monocytic leukemia, which represents 5 per cent of all the cases of leukemia, gingival and other oral changes occur in an extremely high percentage of cases except in edentulous mouths. Indeed, much of the suffering experienced by the patient in monocytic leukemia is related to the pain and discomfort from the necrotic . . .
Surgical Procedures in the DANTE Trial, A Randomized Study of Lung Cancer Early Detection with Spiral Computed Tomography: Comparative Analysis in the Screening and Control Arm
Authors: Maurizio Infante, Giuseppe Chiesa, Daniel Solomon, Emanuela Morenghi, Eliseo Passera, Fabio Romano Lutman, Edoardo Bottoni, Umberto Cariboni, Valentina Errico, Emanuele Voulaz, Giorgio Ferraroli, Alberto Testori, Francesco Inzirillo, Maurizio Chiarenza, Massimo Roncalli, Silvio Cavuto, Arturo Chiti, Marco Alloisio, Gianluigi Ravasi
Journal: Journal of Thoracic Oncology (2010)
Superior sagittal sinus thrombosis and essential thrombocythaemia.
Authors: M F Murphy, C R Clarke, R L Brearley
Journal: BMJ (1983)

intrauterine pregnancies but has little or no effect on the incidence of ectopic pregnancies, and therefore the total number of such pregnancies observed is roughly equal to what would be expected if no contraception had been used.In the past three years we have treated 715 cases with the Yuzpe regimen and had 17 failures, including the present case of an ectopic pregnancy.This rate is compatible with the calculated risk of 1000 for ectopic pregnancies.4We believe that this is the first reported case of an ectopic pregnancy after the Yuzpe regimen.We suggest that patients requesting postcoital treatment should be counselled about this rare but serious complication and warned of the need for prompt examination if they develop severe pelvic pain.Until more evidence is available about the presence or absence of a causative relation between postcoital hor- monal treatment and ectopic pregnancies, the history of previous tubal pregnancy would be a strong contraindication to postcoital treatment.A careful vaginal examination at the follow up visit is important, as vaginal bleeding associated with an ectopic pregnancy can be so easily mistaken for a period, as in our patient.
More Questions Than Answers in 6 Cases
Authors: Jeffrey E. Indes, Alan Dardik
Journal: JAMA Surgery (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Family History and Risk of Ovarian Cancer
Authors: William Foulkes
Journal: JAMA (1995)

To the Editor.  —The recent National Institutes of Health (NIH) Consensus Conference1on ovarian cancer provides physicians with the current consensus regarding the screening, treatment, and follow-up of this disease. Therefore, it is important that this document should be as accurate as possible and reflect the opinions of the experts in the field. We agree that a woman has about a 5% lifetime risk of ovarian cancer if she has a first-degree relative affected with ovarian cancer. For example, in Great Britain, one in 120 women develops ovarian cancer. With one affected first-degree relative, the lifetime risk of ovarian cancer is one in 40 (2.5%), representing a relative risk of 3.2In North America, one in 70 women (1.4%) is affected by ovarian cancer, and the relative risk associated with one affected first-degree relative is about 4, giving a lifetime risk of 5.7%.3,4However, we disagree with
Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans
Authors: Peter Kovacs, Rahel Kress, Jacqueline Rocha, Ulrike Kurtz, Juan Francisco Miquel, Flavio Nervi, Nahum Méndez-Sánchez, Misael Uribe, Hans H. Bock, Ramin Schirin-Sokhan, Michael Stumvoll, Joachim Mössner, Frank Lammert, Henning Wittenburg
Journal: Journal of Hepatology (2007)
Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells
Authors: Wen Sun, Jin Ding, Kun Wu, Bei-Fang Ning, Wen Wen, Han-Yong Sun, Tao Han, Lei Huang, Li-Wei Dong, Wen Yang, Xing Deng, Zhong Li, Meng-Chao Wu, Gen-Sheng Feng, Wei-Fen Xie, Hong-Yang Wang
Journal: Hepatology (2011)

Gankyrin is a critical oncoprotein overexpressed in human hepatocellular carcinoma (HCC). However, the mechanism underlying gankyrin-mediated hepatocarcinogenesis remains elusive. Herein, we provide evidence that gankyrin expression was progressively elevated in liver fibrosis, cirrhosis, and HCC. Levels of gankyrin expression were closely associated with the dedifferentiation status of hepatoma in patients. Decrease of hepatocyte characteristic markers and increase of cholangiocyte-specific markers were observed in rat primary hepatocytes with enforced gankyrin expression and diethylnitrosamine (DEN)-triggered rat hepatocarcinogenesis. Overexpression of gankyrin also attenuated the hepatic function of primary hepatocytes, which further suggests that gankyrin promotes the dedifferentiation of hepatocytes. Moreover, elevated expression of gankyrin closely correlated with the expression of HCC stem/progenitor cell markers in DEN-triggered hepatocarcinogenesis and human HCCs. Hepatoma cells derived from suspension-cultured spheroids exhibited a higher gankyrin level, and enforced gankyrin expression in hepatoma cells remarkably enhanced cluster of differentiation (CD)133, CD90, and epithelial cellular adhesion molecule expression, indicating a role of gankyrin in hepatoma cell dedifferentiation and the generation of hepatoma stem/progenitor cells. In contrast, down-regulation of gankyrin in hepatoma cells by lentivirus-mediated microRNA delivery significantly improved their differentiation status and attenuated malignancy. Interference of gankyrin expression in hepatoma cells also diminished the proportion of cancer stem/progenitor cells and their self-renewal capacity. Furthermore, gankyrin was found to bind hepatocyte nuclear factor 4α (HNF4α), which determines hepatocyte differentiation status and enhances proteasome-dependent HNF4α degradation in hepatoma cells. The inverse correlation of gankyrin and HNF4α was further confirmed in primary hepatocytes, DEN-induced hepatocarcinogenesis, and human HCCs. Conclusion: Gankyrin-mediated dedifferentiation of hepatocytes and hepatoma cells via, at least partially, down-regulation of HNF4α facilitates HCC development, and interference of gankyrin expression could be a novel strategy for HCC prevention and differentiation therapy. (Hepatology 2011;54:1259–1272)
The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/<i>neu</i> Overexpressed/Amplified Breast Cancer
Authors: Chau Dang, Monica Fornier, Steven Sugarman, Tiffany Troso-Sandoval, Diana Lake, Gabriella D'Andrea, Andrew Seidman, Nancy Sklarin, Maura Dickler, Violante Currie, Theresa Gilewski, Mary Ellen Moynahan, Pamela Drullinsky, Mark Robson, Carolyn Wasserheit-Leiblich, Nancy Mills, Richard Steingart, Katherine Panageas, Larry Norton, Clifford Hudis
Journal: Journal of Clinical Oncology (2008)

Purpose Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) is superior to every 3-weekly AC followed by P. Given the demonstrated cardiac safety for trastuzuamb (T) with conventionally scheduled AC followed by P, we tested the safety of dd AC followed by P with T. The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival. Methods Patients with HER-2/neu immunohistochemistry (IHC) 3+ or fluorescent in situ hybridization (FISH)-amplified breast cancer and baseline left ventricular ejection fraction (LVEF) of ≥ 55% were enrolled, regardless of tumor size or nodal status. Treatment consisted of AC (60/600 mg/m 2 ) × 4 followed by P (175 mg/m 2 ) × 4 every 2-weekly with pegfilgrastim (6 mg on day 2) + T ×1 year. LVEF by radionuclide scan was obtained at baseline, at months 2, 6, 9, and 18. Results From January 2005 to November 2005, 70 patients were enrolled. The median age was 49 years (range, 27 to 72 years); median LVEF at baseline was 68% (range, 55% to 81%). At month 2 in 70 of 70 patients, the median LVEF was 67% (range, 58% to 79%); at month 6 in 67 of 70 patients, it was 66% (range, 52% to 75%); at month 9 in 68 of 70 patients, it was 65% (range, 50% to 75%); and at month 18 in 48 of 70 patients, it was 66% (range, 57% to 75%). As of December 1, 2007, the median follow-up was 28 months (range, 25 to 35 months). One patient (1%) experienced conestive heart failure (CHF). There were no cardiac deaths. Conclusion Dose-dense AC followed by P/T followed by T is feasible and is not likely to increase the incidence of cardiac events compared to established regimens.
Fatal attraction: chemokines and type 1 diabetes
Authors: Mark A. Atkinson, S. Brian Wilson
Journal: Journal of Clinical Investigation (2002)

Nonstandard abbreviations used:CC chemokine receptor (CCR); CXC chemokine receptor (CXCR); nonobese diabetic (NOD); monocyte chemoattractant protein (MCP); macrophage inflammatory protein (MIP); regulated on activation, normal T cell expressed and secreted
Thorium Dioxide Myelopathy
Authors: Allan J. D. Dale
Journal: JAMA (1967)

Thorium dioxide (Thorotrast), a radioactive substance with a very long half-life, has been used in the past as a contrast medium for various roentgenologic studies. Some of these have been followed by the delayed appearance of benign and malignant tumors, especially of the liver. Chronic arachnoiditis and myelopathy developed in three patients after myelography with thorium dioxide. Progressive involvement of the cauda equina, spinal cord, and brain stem was observed. One patient died after 26 years of illness.
Moses baskets are a potential health hazard
Authors: M Hesseling, J A Sills
Journal: BMJ (2001)

EDITOR—Moses baskets are commonly used items in households around the country. Some are fitted with carrying handles. Within two months in 2000 we encountered three cases of babies falling out of such baskets after an unintentional slip of the handles; two of these cases resulted in skull fractures. A possible diagnosis of non-accidental injury was ruled out.

Close inspection of the Moses baskets showed that the handles did not seem long enough to meet in the middle (figure). …
Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone
Authors: Tony Reiman, Karen Seeberger, Brian J. Taylor, Agnieszka J. Szczepek, John Hanson, Michael J. Mant, Robert W. Coupland, Andrew R. Belch, Linda M. Pilarski
Journal: Blood (2001)
Acute Dystonic Reaction to Perphenazine
Authors: R. D. Montgomery, V. L. Sutherland
Journal: BMJ (1959)

1ounrI81 215tmzp'cku JoURNAL to his anticonvulsive therapy, and he is disappointed that he has been unable to continue to take this drug.ADDENDUM.-Sincethis paper was submitted, a man aged 57, with glaucoma, has been admitted to Llandough Hospital with typical right renal colic, which occurred during long- term acetazolamide therapy (250-500 mg.daily for three months).The pain lasted 36 hours and there was no oliguria.The previous history and physical findings were not suggestive of renal disorder.Numerous red blood corpuscles and occasional leucocytes were seen on micro- scopical examination of the urine, which was sterile, and an intravenous pyelogram was normal.My thanks are due to Mr. D. B. E. Foster for inviting me to see this patient.
High sensitivity of basophils predicts side‐effects in venom immunotherapy
Authors: M. Kosnik, M. Silar, N. Bajrovic, E. Music, P. Korosec
Journal: Allergy (2005)

Background: Systemic side‐effects of venom immunotherapy (VIT) represent a considerable problem in the treatment of patients allergic to Hymenoptera venom. We examined the hypothesis whether basophil responsiveness might be connected with the adverse reactions to VIT. Methods: Basophil surface expression of activation marker CD63 induced by different concentrations of honeybee and wasp venom (0.1 and 1 μ g/ml) was measured by flow cytometry in 34 patients with history of systemic anaphylactic reactions to Hymenoptera sting just before rush honeybee or wasp VIT. Results: Eleven of 34 patients had systemic anaphylactic reaction (Mueller grades I–III) and one patient a large local reaction to VIT. In those 12 patients, median percentage of activated basophils after stimulation with VIT‐specific venom in concentration of 0.1 μ g/ml was 99% (range: 17–195) of value reached with stimulation with 1 μ g/ml. Side‐effects occurred in all patients with 0.1/1 ratios over 92% (eight of 12). In contrast, in 22 patients with no side‐effects, the median 0.1/1 ratio was 25% (range: 2–92). These concentration‐dependent activation ratios were significantly different between the groups with and without side reactions ( P &lt; 0.0001). We also show significant positive correlation of the occurrence/clinical grade of the side‐effects with individual ratios of CD63 basophil response ( r = 0.73, P &lt; 0.0001). Conclusion: The results suggest that increased basophil sensitivity to allergen‐specific in vitro stimulation is significantly associated with major side‐effects of VIT.
Glucocorticoids inhibit chemokine generation by human eosinophils
Authors: Misato Miyamasu, Yoshikata Misaki, Shinyu Izumi, Toshiaki Takaishi, Yutaka Morita, Haruji Nakamura, Kouji Matsushima, Tadashi Kasahara, Koichi Hirai
Journal: Journal of Allergy and Clinical Immunology (1998)
Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy
Authors: Gillian M. Thomas
Journal: New England Journal of Medicine (1999)

Despite screening programs, approximately 14,000 cases of invasive cervical cancer are diagnosed annually in the United States. In approximately half these cases, locally advanced disease is present at the time of diagnosis. In developing countries, the disease is usually advanced by the time of diagnosis, the prevalence is much higher, and cervical cancer is the principal cause of death due to cancer in women.Pelvic radiation has been the standard, definitive therapy for advanced disease. With this treatment, the overall five-year survival rate is approximately 65 percent, but it ranges from 15 to 80 percent, depending on the extent of . . .
A "PRECISION MEDICINE" STRATEGY FOR RECURRENT GLIOBLASTOMA
Authors: M. Prados
Journal: Neuro-Oncology (2014)

BACKGROUND: Despite years of intense clinical research and clinical trials, there are essentially no effective therapies proven to increase survival at the time of tumor progression in Glioblastoma. Multiple strategies, primarily focused on targeted single agent approaches, have failed for a number of reasons. Newer approaches and strategies are needed. METHODS: The Ivy Foundation Early Phase Clinical Trials Consortium took the strategy that an agnostic approach, using tumor tissue obtained prior to any treatment decisions and interrogated using an extensive molecular profiling paradigm could be the basis for an informed treatment decision based upon individual patient genotypes. The goal of the Consortium was to develop a protocol designed to define individualized patient treatments, using a specialized molecular tumor board, within a reasonable time from the date of surgery. RESULTS: After extensive discussion about methods, endpoints, and specific types of genomic testing, focusing on a whole genome approach, a feasibility trial was designed, ultimately allowing for treatment using up to 4 drugs from the entire USA FDA approved Pharmacopia. Tumor tissue obtained from the "core" of the lesion and multiple image guided biopsies of regions surrounding the core are profiled, reported to the tumor board with specific drug recommendations, and a final report given to the treating physician. CONCLUSIONS: The clinical trial design and strategy will be discussed, including the primary and secondary aims, and the regulatory process involved to allow the trial to open. Early results will be presented. SECONDARY CATEGORY: n/a.
No Smallpox at Little Rock.
Authors: L. P. Gibson
Journal: JAMA (1895)

Little Rock, Ark., April 1,1895. <h3>To the Editor:</h3> —In the issue of theJournalfor March 23, page 454, under the heading "Health Reports," it is stated that from February 1 to March 8, eighty-two cases of smallpox and fourteen deaths have occurred at<i>Little Rock!</i>The report was sent out from the latter place and the error doubtless occurred from that fact, while Hot Springs is the place where the disease has existed and the figures refer thereto. There is no smallpox in Little Rock, but we have the Legislature. Very respectfully,